Gitnux/Report 2026

Research Peptides Industry Statistics

The global research-peptide market reached $617 million in 2024, explore the latest available figures on growth, companies and trends.
18Statistics
25Sources
4Sections
1Visuals
15mRead
Research Peptides Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The research peptides industry at a glance

The standalone research-use-only peptide market is not reliably measured; the adjacent peptide manufacturing industry is expanding, with Bachem reporting CHF 695.1 million in 2025 sales, up 14.8% year over year.

CHF 695.1M[11]
Bachem sales, 2025
14.8%[11]
Bachem sales growth, 2025
13.8%
Bachem peptide CRDMO share, 2023
2,511[11]
Bachem employees, 2025
Market size
No reliable public estimate isolates research-use-only peptides from therapeutic peptides, pharmaceutical APIs, and laboratory reagents. As a measurable industry proxy, Bachem reported CHF 695.1 million in 2025 sales across its peptide and oligonucleotide-focused business, compared with CHF 605.3 million in 2024.[11]
Forecast & CAGR
Public forecasts generally cover the broader peptide therapeutics or peptide contract-manufacturing markets rather than research-use-only products. Grand View Research forecasts the peptide contract-manufacturing market through 2033, while its 2025 material identifies North America as the leading regional market; a standalone research-peptide CAGR could not be verified from a primary source.[12]
Market share & regions
The peptide CRDMO market is internationally supplied, with major companies operating across North America, Europe, and Asia. A 2025 Hong Kong Exchange industry overview reported Bachem at 13.8% of the global peptide CRDMO market in 2023 and described its geographic coverage as Europe, the United States, and Asia.
Segmentation
Research peptides are commonly sold as catalog compounds, custom-synthesis projects, and peptide blends, while industrial peptide services are segmented into development, clinical supply, commercial API manufacturing, purification, and lyophilization. Bachem reported 2025 sales of CHF 343.4 million in commercial APIs and CHF 304.0 million in CMC development, although these categories include oligonucleotide activity as well as peptides.[11][13]
Key players & concentration
The market is fragmented at the retail research-supplier level, but peptide manufacturing has identifiable scaled specialists. Bachem held 13.8% of the global peptide CRDMO market in 2023, according to a Hong Kong Exchange industry overview; its 2025 workforce was 2,511 employees and its sales were CHF 695.1 million.[11]
Pricing
Published 2026 research-reagent prices vary substantially by sequence, purity, vial size, and supplier. Apex Lab listed 64 milligram-denominated materials, with examples ranging from $0.75 per milligram for AICAR to $140 per milligram for ACE-031; these are catalog prices for laboratory research material, not pharmaceutical or treatment prices.[13]
Trends, drivers & challenges
Demand is being supported by peptide drug discovery, GLP-1-related manufacturing investment, and outsourcing of synthesis and analytical work. The main challenges are sequence-specific manufacturing complexity, impurity and characterization requirements, supply-chain concentration, and the risk that products labeled for research use are diverted for human use; the FDA identifies limited safety information and potential risks for several peptide substances used in compounding.[11][9]
Consumer behavior & competition
Research-peptide purchasing is increasingly conducted through online catalogs that compete on price, catalog breadth, certificates of analysis, stated purity, and shipping speed. One 2026 catalog listed 64 materials and explicitly distinguished research-reagent pricing from pharmaceutical and compounded-drug economics, illustrating the absence of standardized retail pricing.[13][14]
M&A
Consolidation is continuing among peptide manufacturers and CDMOs. In May 2026, CordenPharma agreed to acquire AmbioPharm, adding peptide API development and manufacturing facilities in South Carolina and Shanghai; the acquisition closed on August 3, 2026.[5]
Regulation
In the United States, research-use-only labeling does not make an unapproved peptide lawful for human administration. The FDA states that certain bulk peptide substances may present significant safety risks and notes limited or absent safety-related information for some substances; enforcement and compounding rules remain a material commercial risk for online sellers.[9]
Latest news
The most recent directly relevant corporate development located was CordenPharma's August 3, 2026 completion of its AmbioPharm acquisition. The transaction adds facilities in South Carolina and Shanghai and expands CordenPharma's peptide development, clinical-supply, and commercial-manufacturing footprint.[5]

02 Ranking

Top 10 Companies in the Research Peptides Industry

The leading companies in the research peptides industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

GenScript Biotech stands out for custom research peptide delivery because it delivered over 600,000 custom peptides to more than 10,000 scientists worldwide, while Thermo Fisher Scientific focuses on custom peptide scope since it offers custom peptides from 2–110 amino acids at research scales up to 1 kg+.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in custom research peptides

    GenScript Biotech

    CN

    Ranked #1 · 9.4 · Custom research peptides

    Why we picked it: Its custom research peptide scale is supported by delivering over 600,000 peptides to more than 10,000 scientists worldwide.

  2. Leader in peptide and oligonucleotide manufacturing

    Bachem

    CH

    Ranked #3 · 8.9 · Peptide and oligonucleotide manufacturing

    Why we picked it: Its 2025 peptide and oligonucleotide-focused sales reached CHF 695.1 million, with 14.8% year over year growth.

  3. Leader in research-grade peptide CRDMO

    Medtide

    Ranked #4 · 8.9 · Research-grade peptide CRDMO

    Why we picked it: It supplies peptide services across discovery, development, and commercial production via CPC Scientific.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the research peptides industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

GenScript Biotech

Custom research peptides · CN

9.4
2

Thermo Fisher Scientific

Custom research peptides · US

9.0
3

Bachem

Peptide and oligonucleotide manufacturing · CH

8.9
4

Medtide

Research-grade peptide CRDMO

8.9
5

Merck KGaA

Custom research peptides · DE

8.8
6

CPC Scientific

Research-grade peptide synthesis and peptide CRDMO, global · US

8.6
7

PolyPeptide Group

Custom research-grade and therapeutic peptides, global · CH

8.4
8

Biosynth

Custom and catalog research peptides, global · CH

8.2
9

Creative Peptides

Custom research, modified and complex peptides, global · US

8.0
10

Phoenix Pharmaceuticals

Catalog and custom research peptides, US and global · US

7.9

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the research peptides industry. In Research Peptides Industry Statistics. Gitnux. https://gitnux.org/research-peptides-industry-statistics/#top-companies

report visual · Comparison

Research peptide suppliers based in country

United Kingdom leads with 353.

United Kingdom353
United States293
Australia59
Canada42
Netherlands30
Germany26
source-verifiedpepfinder.com

04 Statistics

Market Intelligence

Supplier and listing counts show a wide retail and directory footprint, with 45,351 live research-peptide product listings tracked globally as of 19 November 2026.

Market size, volume and shipments in the research peptides industry

  • $617 million was the estimated global 2024 research-peptide market value, covering research-use peptide products; the estimate is attributed to Grand View Research by the dataset publisher.[1]

Company counts and size structure in the research peptides industry

  • 195 UK-facing research-peptide retailers were classified in August 2026, from 211 sellers tracked in the report.[2]
  • 1,008 research-peptide suppliers were tracked globally as of 19 November 2026; PepFinder states this is a directory count, not an estimate of the whole market.[3]
  • 45,351 live research-peptide product listings were tracked globally as of 19 November 2026 across 100 peptides.[3]

Regional split of the research peptides industry

  • 381 suppliers served the United States in October 2026, comprising 311 based there and 70 overseas suppliers stating that they shipped into the country.[3]
  • 211 UK-facing sellers were tracked in August 2026, including 195 classified as research-peptide retailers.[2]
  • 416 suppliers served the United Kingdom in October 2026, comprising 362 based there and 54 overseas suppliers stating that they shipped into the country.[3]

05 Statistics

Strategy & Growth

Capacity and manufacturing expansion figures point to investment in peptide production modules, including up to 18,000 litres of reactor capacity planned in India.

Capacity expansion in the research peptides industry

  • Up to 18,000 litres of reactor capacity is planned for Neuland Laboratories’ second commercial peptide-manufacturing module in India.[4]
  • More than €500 million will fund CordenPharma’s Basel-region greenfield peptide facility, with total SPPS reactor capacity exceeding 5,000 litres.[5]
  • More than €1 billion was committed over three years to CordenPharma’s peptide development and manufacturing expansion worldwide, including a Basel-region greenfield facility.[5]

06 Statistics

Production & Operations

2026 testing results highlight quality and labeling gaps, including 71.1% of tested gray-market samples failing standards for 95–105% label abundance and at least 99.5% purity.

Defects and conformance in the research peptides industry

  • 15% of research-peptide samples with available endotoxin results had detectable endotoxin contamination in 2026; the study covered 6,441 consumer-tested samples but did not treat the result as market-wide.[6]
  • 71.1% of 6,441 tested gray-market research-peptide samples failed the study’s manufactured-drug standards for 95–105% label abundance and at least 99.5% purity in 2026; dataset scope was 14 peptides sold directly to consumers.[6]
  • 23 of 202 research-peptide vendors with certificates—11.4%—published all eight specified certificate elements, including purity, chromatography, lot, mass spectrometry, verification, contamination testing and accreditation, in 2026.[7]
  • 0.69% of 54,306 voluntarily submitted research-peptide laboratory records with identity results failed to match the labeled compound in TitrateLab’s August 8, 2026 extraction.[8]
  • 6.92% of 43,774 voluntarily submitted research-peptide tests measured more than 10% less peptide than the label stated in TitrateLab’s August 8, 2026 extraction.[8]

07 Statistics

Regulation & Risk

Regulatory actions in the U.S. were active in 2026, with 6 FDA warning letters cited for research-peptide sellers or peptide manufacturers from April through September 2026.

Enforcement and penalties in the research peptides industry

  • 6 FDA warning letters identified research-peptide sellers or peptide manufacturers in the United States from April through September 2026; actions cited unapproved, misbranded or adulterated products.[9]
  • 70 months’ imprisonment and $78,317.52 restitution were imposed in July 2026 on the owner of Paradigm Peptides for selling unapproved peptides and other drugs interstate.[10]
  • 21 months’ imprisonment was imposed in July 2026 on a distributor involved in importing and selling unapproved peptide products from China in the United States.[10]

Key questions about the research peptides industry

What is the estimated size of the research-use peptide market?
The global 2024 research-peptide market is estimated at $617 million, covering research-use peptide products.
Is the market growing, and what rate should we use?
A standalone research-peptide CAGR could not be verified from a primary source because public forecasts usually cover broader peptide therapeutics or peptide contract-manufacturing markets.
Which companies lead the research peptides industry?
GenScript Biotech stands out for custom research peptide delivery because it delivered over 600,000 custom peptides to more than 10,000 scientists worldwide, while Thermo Fisher Scientific focuses on custom peptide scope since it offers custom peptides from 2–110 amino acids at research scales up to 1 kg+.
What technology or capacity shifts matter for research-peptide supply?
Capacity investments broaden global supply, with example plans including up to 18,000 litres of reactor capacity in India for Neuland Laboratories.
How is the supplier landscape structured for research peptides?
Retail suppliers are fragmented, while peptide manufacturing has identifiable scaled specialists; 1,008 research-peptide suppliers were tracked globally as of 19 November 2026 in a directory count.
What compliance and quality signals are most often reported in 2026 datasets?
In 2026, 15% of samples with available endotoxin results had detectable endotoxin contamination, while 71.1% of 6,441 gray-market samples failed manufactured-drug standards for 95–105% label abundance and at least 99.5% purity.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Research Peptides Industry Statistics. Gitnux. https://gitnux.org/research-peptides-industry-statistics
MLA
Samuel Norberg. "Research Peptides Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/research-peptides-industry-statistics.
Chicago
Samuel Norberg. 2026. "Research Peptides Industry Statistics." Gitnux. https://gitnux.org/research-peptides-industry-statistics.